Progranulin gene variability influences age of onset and clinical course of relapsing-remitting multiple sclerosis

被引：0
作者：
Vercellino, M.
Cavalla, P.
Fenoglio, C.
Mattioda, A.
Romagnolo, A.
Matta, M.
De Riz, M.
Dematteis, F.
Giobbe, D.
Scarpini, E.
Giordana, M. T.
Galimberti, D.
机构：
[1] Univ San Giovanni Battista, Turin, Italy
[2] IRCCS Osped Maggiore Policlin, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P756
引用
收藏
页码：S335 / S335
页数：1
相关论文
共 50 条
[21]   Natalizumab for relapsing-remitting multiple sclerosis [J].
Horga, A. ;
Tintore, M. .
NEUROLOGIA, 2011, 26 (06) :357-368
[22]   The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades [J].
Romero-Pinel, Lucia ;
Bau, Laura ;
Matas, Elisabet ;
Leon, Isabel ;
Munoz-Vendrell, Albert ;
Arroyo, Pablo ;
Masuet-Aumatell, Cristina ;
Martinez-Yelamos, Antonio ;
Martinez-Yelamos, Sergio .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
[23]   Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study [J].
Siokas, Vasileios ;
Katsiardanis, Konstantinos ;
Aloizou, Athina-Maria ;
Bakirtzis, Christos ;
Liampas, Ioannis ;
Koutlas, Evangelos ;
Rudolf, Jobst ;
Ntinoulis, Konstantinos ;
Kountouras, Jannis ;
Dardiotis, Efthimios ;
Deretzi, Georgia .
NEUROLOGY INTERNATIONAL, 2021, 13 (04) :517-526
[24]   Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis [J].
Achiron, A ;
Barak, Y ;
Rotstein, Z .
MULTIPLE SCLEROSIS, 2003, 9 (05) :486-491
[25]   Course of relapsing-remitting multiple sclerosis before, during and after natalizumab [J].
Kaufman, Michael D. ;
Lee, R. ;
Norton, H. J. .
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (04) :490-494
[26]   Neurotrophic factors and clinical recovery in Relapsing-Remitting multiple sclerosis [J].
Caggiula, M ;
Batocchi, AP ;
Frisullo, G ;
Angelucci, F ;
Patanella, AK ;
Sancricca, C ;
Nociti, V ;
Tonali, PA ;
Mirabella, M .
NEUROLOGY, 2004, 62 (07) :A115-A115
[27]   The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis [J].
Namaka, M ;
Pollitt-Smith, M ;
Gupta, A ;
Klowak, M ;
Vasconcelos, M ;
Turcotte, D ;
Gong, YW ;
Melanson, M .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (02) :223-239
[28]   Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis [J].
Caggiula, M ;
Batocchi, AP ;
Frisullo, G ;
Angelucci, F ;
Patanella, AK ;
Sancricca, C ;
Nociti, V ;
Tonali, PA ;
Mirabella, M .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2005, 62 (02) :176-182
[29]   Clinical features of 314 patients with relapsing-remitting multiple sclerosis [J].
Nogales-Gaete, Jorge ;
Aracena, Rodrigo ;
Cepeda-Zumaeta, Sergio ;
Eloiza, Claudio ;
Agurto, Paula ;
Diaz, Vannia ;
Labbe, Silvia ;
Martinez, Sefora ;
Flores, Jazmin ;
Araya, Casandra .
REVISTA MEDICA DE CHILE, 2014, 142 (05) :559-566
[30]   Altered functional connectivity and performance variability in relapsing-remitting multiple sclerosis [J].
Wojtowicz, Magdalena ;
Mazerolle, Erin L. ;
Bhan, Virender ;
Fisk, John D. .
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (11) :1453-1463
12345